Glycemic control on development of chronic heart failure in patients with type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-5513
Abstract
Aims.
To assess contribution of therapeutic training, blood glucose self-monitoring and general improvement of glycemic control on development ofchronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM).
Materials and methods.
We conducted a prospective, open-label, non-controlled before/after study. 80 patients with T2DM took part in this trialafter initial hospitalization for decompensation of both CHF and diabetes (НbА1с>=8.0%). Therapeutic training as well as provision of tools and consumablesfor self-monitoring was arranged for all patients. Therapeutic goal was set to lowering НbА1с for?1% by the end of 12 months of follow-up.
Results.
We observed lowering of НbА1с values from 9.3% [8,4-10,6] to 8.8% [7,6-10,0] (р<0.001), while number of patients with regular hypoglycemicexperience decreased from 25 (35%) to 10 (14%), р=0.003. 28 patients (39%) reached the therapeutic goal. CHF progression was observedin 9 patients (32%) from this subgroup, as compared with 25 patients (57%) from the subgroup which failed to reach the therapeutic goal (p=0.04).
Conclusion.
Therapeutic training and regular self-monitoring are effective in improvement of glycemic control in patients with T2DM and CHF.Decrease in НbА1с for?1% by 12 months results in deceleration of CHF progression in patients with T2DM.
To assess contribution of therapeutic training, blood glucose self-monitoring and general improvement of glycemic control on development ofchronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM).
Materials and methods.
We conducted a prospective, open-label, non-controlled before/after study. 80 patients with T2DM took part in this trialafter initial hospitalization for decompensation of both CHF and diabetes (НbА1с>=8.0%). Therapeutic training as well as provision of tools and consumablesfor self-monitoring was arranged for all patients. Therapeutic goal was set to lowering НbА1с for?1% by the end of 12 months of follow-up.
Results.
We observed lowering of НbА1с values from 9.3% [8,4-10,6] to 8.8% [7,6-10,0] (р<0.001), while number of patients with regular hypoglycemicexperience decreased from 25 (35%) to 10 (14%), р=0.003. 28 patients (39%) reached the therapeutic goal. CHF progression was observedin 9 patients (32%) from this subgroup, as compared with 25 patients (57%) from the subgroup which failed to reach the therapeutic goal (p=0.04).
Conclusion.
Therapeutic training and regular self-monitoring are effective in improvement of glycemic control in patients with T2DM and CHF.Decrease in НbА1с for?1% by 12 months results in deceleration of CHF progression in patients with T2DM.
About the Authors
Leonid Grigor'evich Strongin
Nizhny Novgorod State Medical Academy, Nizhny Novgorod
Il'ya Grigor'evich Pochinka
Nizhny Novgorod State Medical Academy, Nizhny Novgorod
Maria Sergeevna Konysheva
Nizhny Novgorod State Medical Academy, Nizhny Novgorod
Elena Pavlovna Morozova
Nizhny Novgorod State Medical Academy, Nizhny Novgorod
References
1. MacDonald MR, Petrie MC, Hawkins NM, McMurray JJ. Diabetes, left ventricular systolic dysfunction and chronic heart failure. Diabetic cardiology. Wiley; 2007. p. 93-134.
2. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Rydén L. The association between glucose abnormalities and heart failure in the population-based. Reykjavik study. Diabetes Care. 2005 Mar;28(3):612-616.
3. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004 Mar;27(3):699-703.
4. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006 Jan;27(1):65-75. Epub 2005 Oct 11.
5. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ. Diabetes, left ventricular systolic dysfunction and chronic heart failure. Eur Heart J. 2008 May;29(10):1224-1240. Epub 2008 Apr 18.
6. Стронгин ЛГ, Починка ИГ, Алейник ДЯ, Чарыкова ИН. Предикторы выживаемости больных хронической сердечной недостаточностью, страдающих сахарным диабетом 2 типа. Сахарный диабет. 2004;(4):14-18.
7. Стронгин ЛГ, Ботова СН, Починка ИГ. Прогностическое значе- ние кардиоваскулярной автономной нейропатии у больных с сочетанием сахарного диабета 2-го типа и хронической сердечной недостаточности. Кардиология. 2010;(2):26-29.
8. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional Risk Factors for Cardiovascular Disease in Diabetes. Endocr Rev. 2004 Feb;25(1):153-175.
9. Северина АС, Шестакова МВ. Нарушение системы гемостаза у больных сахарным диабетом. Сахарный диабет. 2004;(1):62-67.
10. Починка И.Г. Особенности продукции фактора некроза опухоли у больных хронической сердечной недостаточностью, страдающих сахарным диабетом 2-го типа. Сборник статей X межрегионального кардиологического форума. Нижний Новгород; 2006. с. 135 - 138.
11. Fang ZY, Prins JB, Marwick TH. Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications. Endocr Rev. 2004 Aug;25(4):543-567.
12. van Melle JP, Bot M, de Jonge P, de Boer RA, van Veldhuisen DJ, Whooley MA. Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease. Diabetes Care. 2010 Sep;33(9):2084-2089.
13. Goode KM, John J, Rigby AS, Kilpatrick ES, Atkin SL, Bragadeesh T, Clark AL, Cleland JG. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart. 2009 Jun;95(11):917-923. Epub 2009 Feb 19
14. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S; CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008 Aug 11;168(15):1699-1704.
15. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009 Jul 28;54(5):422-428.
16. Weinrauch LA, Lewis EF. Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes the "sweet spot". J Am Coll Cardiol. 2009 Jul 28;54(5):429-431.
17. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007 Sep 8;335(7618):497. Epub 2007 Aug 30.
18. Лапина ЮВ, Филатов ДН, Мареев ВЮ, Нарусов ОЮ, Болотина МГ, Шестакова МВ, Масенко ВП, Литонова ТН, Бакланова НА, Беленков ЮН. Влияние строго гликемического контроля на клиническое состояние и течение заболевания у пациентов с хронической сердечной недостаточностью и сахарным диабетом 2-го типа. Результаты исследования «рациональная эффективная многокомпонентная терапия в борьбе с сахарным диабетом у больных ХСН» (РЭМБО-СД ХСН). Кардиология. 2008;48(9):17 - 27.
Review
For citations:
Strongin L.G., Pochinka I.G., Konysheva M.S., Morozova E.P. Glycemic control on development of chronic heart failure in patients with type 2 diabetes mellitus. Diabetes mellitus. 2012;15(2):17-21. (In Russ.) https://doi.org/10.14341/2072-0351-5513
Views:
1201
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
